Impact of Nirsevimab on bronchiolities in pediatric primary care in Lazio Region: an observational study

Abstract Background Bronchiolitis is the leading cause of lower respiratory tract infections in infants, with respiratory syncytial virus (RSV) as the primary pathogen. Nirsevimab, a long-acting monoclonal antibody, was introduced in Europe in late 2022 for RSV prophylaxis in all infants. In Italy,...

Description complète

Détails bibliographiques

Auteurs principaux:	Daniele Petrone, Ilaria Sani, Valentina De Vittori, Silvana Brenna, Pietro Luigi Rotili, Maria Teresa Fonte, On behalf of the Scientific Committee of the Italian Pediatrician Federation (FIMP), Rome, Italy
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2026-03-01
Collection:	Italian Journal of Pediatrics
Sujets:	Nirsevimab Immunization RSV Prevention
Accès en ligne:	https://doi.org/10.1186/s13052-026-02221-w
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!